NovaBay Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
SDEV$0.89-9.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
|---|
The financial statements required by this Item 8 are set forth below. Our quarterly financial information is set forth in Item 7 of this report and is hereby incorporated into this Item 8 by reference.
| INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | |
|---|---|
| Page | |
| Report of Independent Registered Public Accounting Firm | 25 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 28 |
| Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 | 29 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | 30 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | 31 |
| Notes to Consolidated Financial Statements | 32 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.